Tuesday, February 23, 2010

“Malaysia to host international conference on caning of women (New Kerala)” plus 2 more

“Malaysia to host international conference on caning of women (New Kerala)” plus 2 more

Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction.

Malaysia to host international conference on caning of women (New Kerala)

Posted: 23 Feb 2010 02:48 AM PST

Message from fivefilters.org: If you can, please donate to the full-text RSS service so we can continue developing it.

Kuala Lumpur, Feb 23 : An international conference on comparative studies by Muslim nations on whether it is the norm for Muslim women to be caned for an offence under the Shariah law will be held in Malaysia.

Malaysian Women, Family and Community Development Minister Shahrizat Abdul Jalil hoped the conference could be held in three months to address the issue.

"I will bring this up with the Cabinet as soon as possible," The Star quoted Jalil, as saying.

She said the ministry will organize the conference through the Secretariat for the Defence and Empowerment of Women, adding that Ulamas and NGOs would also have their forums at the conference.

The initiative for the caning comes after caning of three Malaysian women, who were found guilty of committing illicit sex in violation of Shariah law, caught immediate international reaction and interest, with a number of foreign media running articles and commentary on the issue.

The three women were sentenced to be whipped under Section 23(2) of the Federal Territory Shariah Criminal Offences Act 1997 (Illicit Sex) for engaging in illicit sex.

Several organizations in Malaysia, including Sisters in Islam (SIS) had earlier said the three cases constituted further discrimination against Muslim women in Malaysia.

Bar Council chairman Ragunath Kesavan urged the Government to abolish whipping and to comply with international norms and principles on it.

--ANI

Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction.

Chiltern International and Charles River Laboratories to study radiolabelled drug products (News-Medical-Net)

Posted: 22 Feb 2010 08:57 PM PST

Message from fivefilters.org: If you can, please donate to the full-text RSS service so we can continue developing it.

Chiltern International Limited, a global contract research organization (CRO), announced its latest collaboration with Charles River Laboratories, Inc. As part of this collaboration, Chiltern Early Phase will partner with Charles River to conduct and support early phase radiolabelled studies.

Glenn Kerkhof, Chiltern CEO, stated, "This new partnership is an exciting collaboration. Charles River's reputation is world-renowned for their conduct of studies using radiolabelled investigational products.  Their extensive experience includes submission and review procedures for radiolabelled studies in man, including dosimetry calculations and submission to ARSAC. The clinical aspects of the radiolabelled studies will be performed by Chiltern Early Phase in Dundee, Scotland. These complementary strengths add a new dimension to the full CRO services that Chiltern already provides, continuing to demonstrate our commitment to providing our clients with the highest standard of quality and expertise."

Chiltern Early Phase has a dedicated 42-bed clinical pharmacology unit located in a UK National Health Service hospital and leading medical school. Established in 1982, Chiltern Early Phase has performed more than 700 clinical pharmacology studies in all routes of administration across major therapeutic areas. With more than 27 years of experience, Chiltern Early Phase has robust processes in place and its hospital-based location provides a full suite of safety monitoring with 24/7 access to hospital-based crash teams and hospital specialists for therapeutic area expertise and patient recruitment. In addition, Chiltern Early Phase offers an extensive database of healthy volunteers and other patient populations. Chiltern Early Phase's long pedigree in clinical pharmacology combined with Charles River's radiolabel capabilities are poised to provide the industry with unrivalled experience and expertise in early phase radiolabelled ADME studies.

The Metabolism and Pharmacokinetics group at Charles River, Edinburgh, have been conducting radiolabelled trials in man for more than 20 years. The facility includes a GMP clean room, licensed for the manufacture of radiolabelled drug products, including aseptic products for parenteral use. The close proximity of the laboratories allows a rapid turn around of radioactivity data (within 24 hours). Human metabolites can also be characterised by liquid chromatography with accurate mass, mass spectroscopy and concurrent radio-detection.

SOURCE Chiltern

Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction.

Geneombio plans more regulatory submissions to grab international business (PharmaBiz)

Posted: 22 Feb 2010 06:37 PM PST

Message from fivefilters.org: If you can, please donate to the full-text RSS service so we can continue developing it.

Tuesday, February 23, 2010 08:00 IST
Gireesh Babu, Mumbai

The Pune-based Geneombio Technologies Ltd, a contract research firm in the field of DNA-based testing services, is lining up for a set of regulatory filings to make its laboratory eligible to carry out more tests in compliance with national and international regulatory standards.

The company, which has recently received ISO/IEC 17025: 2005 for complying with the international standards for management and testing requirements, is now planning to get the Good Laboratory Practices (GLP) compliance from the National GLP Compliance Monitoring Authority (NGCMA).

GLP certification seeks to ensure the non-hazardous nature of the pharma, veterinary and cosmetic product at the plant and to follow the guidelines conceived by the Organisation for Economic Co-operation and Development (OECD).

"National GLP Compliance Monitoring Authority was established by the Department of Science & Technology, Government of India, with the approval of the Union Cabinet on April 24, 2002. Compliance with this standard will open us more opportunity to the member countries of OECD," said Sachin Purohit, managing director, Geneombio. The GLP-compliance Certification, which is based on the managerial and technical level quality of standards, is valid for a period of three years.

The NGCMA issues GLP on various fields including physical-chemical testing, toxicity studies, mutagenicity studies, environmental toxicity studies on aquatic and terrestrial organisms, studies on behaviour in water, soil and air, bio-accumulation, residue studies, studies on effects on mesocosms and natural ecosystems, analytical and clinical chemistry testing including other areas of laboratory testing services

At present, almost 15 facilities run by major pharma companies like Ranbaxy Laboratories, Dr Reddy's Laboratories, Zydus Research Centre, Advinus Therapeutics, Reliance Life Sciences and Orchid Research Lab along with government run laboratories like the National Toxicology Centre under the National Institute of Pharmaceutical Education and Research (NIPER), Mohali, are accredited by the NGCMA.

Simultaneously, the company is filing documents with the National Accreditation Board for Testing and Calibrating Laboratories (NABL) for ISO 15189:2007, which specifies requirements for quality and competence particular to medical laboratories. If received, the certificate would accredit the company as an eligible laboratory facility to issue clinical reports on any pathology tests.

ISO 15189:2007 is an accreditation used by medical laboratories in developing their quality management systems and assessing their own competence, and for use by accreditation bodies in confirming or recognising the competence of medical laboratories.

The company is planning to apply for these accreditation within next couple of months, and has expectations in business revenue from these services eventually, said Purohit.

Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)